TRINETRA › Sectors › Healthcare
Artemis Medicare Services Limited (ARTEMISMED) — share price, P/E and fundamentals
Artemis Medicare Services Limited (NSE: ARTEMISMED) closed at ₹293.20 on 30 Oct 2026, +20.2% over one year, against a 52-week range of ₹203.35 – ₹378.80.
In the quarter ended 30 Sept 2026 (consolidated, filed 30 Oct 2026) it reported revenue of ₹311 cr and net profit of ₹31 cr, a 10.0% net margin; revenue grew 13.2% and profit grew 4.1% year on year.
On four consecutive filed quarters its trailing P/E is 40.5; since 18 Aug 2025 its own P/E has ranged from 33.5 to 53.6 (median 43.5), and today's reading is higher than 27% of those 295 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 12.5%, ROCE 14.5%, debt-to-equity 0.24, Piotroski F-score 7 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 23% of 64 sector peers; PBT margin higher than 27% of 64 sector peers; ROE higher than 45% of 64 sector peers.
Key figures
| Last close | ₹293.20 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -11.9% / +25.2% / +20.2% |
| 52-week low – high | ₹203.35 – ₹378.80 |
| Market capitalisation | ₹4,642 cr |
| Trailing P/E | 40.5 |
| Price / book | 4.69 |
| EV / EBITDA | 20.9 |
| Earnings yield | 2.5% |
| TTM EPS | ₹7.25 |
| TTM net profit | ₹115 cr |
| Quarter revenue | ₹311 cr |
| Quarter net profit | ₹31 cr |
| Net margin | 10.0% |
| Revenue growth (YoY) | +13.2% |
| Profit growth (YoY) | +4.1% |
| Return on equity | 12.5% |
| ROCE | 14.5% |
| Debt / equity | 0.24 |
| Current ratio | 1.82 |
| Free cash flow | ₹-0 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹9.1 cr |
Against Healthcare peers
| Metric | ARTEMISMED | Peer median | Percentile |
|---|---|---|---|
| Net margin | 9.98 | 12.89 | 23 |
| PBT margin | 13.17 | 17.68 | 27 |
| ROE | 12.54 | 13.87 | 45 |
| ROCE | 14.50 | 17.26 | 34 |
| Debt / equity | 0.24 | 0.11 | 64 |
| FCF margin | -0.01 | -0.87 | 53 |
| Cash conversion | 1.80 | 1.25 | 77 |
| Trailing P/E | 40.46 | 43.26 | 43 |
Questions
What is the P/E ratio of Artemis Medicare Services Limited?
Artemis Medicare Services Limited's trailing P/E is 40.5, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 18 Aug 2025 its P/E has ranged 33.5–53.6.
What were Artemis Medicare Services Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Artemis Medicare Services Limited reported revenue of ₹311 cr and net profit of ₹31 cr (consolidated), filed with the exchange on 30 Oct 2026.
What is Artemis Medicare Services Limited's ROE?
Return on equity is 12.5% based on the balance sheet dated 30 Sept 2026.
Does Artemis Medicare Services Limited have debt?
Debt-to-equity is 0.24 on the balance sheet dated 30 Sept 2026.
What is ARTEMISMED's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, ARTEMISMED traded between ₹203.35 and ₹378.80.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.